Generic Drug Settlement Prompts More FTC Scrutiny
This marks another development in the FTC’s campaign to regulate possible anti-competitive effects stemming from deals that keep generic alternatives to brand name drugs off the market.
“We feel confident that our settlements comply with the law,” said Robert Grupp, Cephalon’s vice president of public affairs.
Grupp wouldn’t speculate about the possible outcome of the FTC probe, but reiterated that the settlements were...
To view the full article, register now.